Heracles Pharma Seeks to Develop Strategic Partnerships with Pharmaceutical Industry in Pursuit of FDA Approval and Commercialization of X-22 Very Low Nicotine Smoking Cessation Product CLARENCE, N.Y.– XXII, (BUSINESS WIRE)– 22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that 22nd Century has launched a new website atwww.heraclespharma.com to highlight the Company’s X-22 Very Low Nicotine smoking cessation cigarette in development. With 95% less nicotine than conventional tobacco, X-22Read more
- Co-Diagnostics, Inc. Announces Construction Update at JV Manufacturing Facility in India
- Cannabis Strategic Files Provision Patent for Unique Cannabis Smoke Filtration Device
- Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with CellBridge Incorporated
- Pura Naturals Launches New Line of Health and Beauty Products with CBD and Hemp Seed Oils
- Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with 48Hour Discovery
SMALL CAP MARKET NEWS
We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.
LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!
Stock Investors · Accredited Investors · Hedge Fund InvestorsLearn More